Is AbbVie a Good Dividend Stock to Buy on the Dip?
The week that ended Jan. 13 was a relatively good one for the stock market overall. But AbbVie (NYSE: ABBV) shares weren't invited to the party. The dividend-paying pharmaceutical stock ended the week 7.8% lower.
Is AbbVie's recent dip the first of many, or could it be an opportunity to scoop up a high-yield dividend stock at a discount? To answer those questions, we need to start with the reason it fell in the first place.
The first thing any investor should know about AbbVie is that its most significant revenue stream, Humira, is under pressure. The FDA first approved the inflammation-controlling injection way back in 2002, and it's finally beginning to experience competition from lower-cost biosimilar versions.
Source Fool.com
